The Connector's Corner — July 16, 2026

A NOTE FROM RONITH

Hi friends,

It's been a full week on the ground — calls with biotech teams building out patient advocacy functions, candidates who bring lived experience to the table, and nonprofits doing the quiet, unglamorous work of showing up for patients every single day. That's the thread running through this issue: the best outcomes in rare disease happen when talent, advocacy, and community pull in the same direction. Grab your coffee and let's dig in.

INDUSTRY PULSE

It was a big week for deal-making and approvals. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for roughly $10 billion in equity value, adding an approved oral acromegaly therapy and a Phase III candidate for congenital adrenal hyperplasia to its rare-endocrine pipeline. United Therapeutics also moved on the M&A front, acquiring Thymmune Therapeutics for $140 million upfront plus up to $160 million in milestones. On the regulatory side, ARPA-H announced up to $160 million across its THRIVE program to fund personalized gene-editing platforms for rare pediatric diseases, with awards going to Children's Hospital of Philadelphia and a Jackson Laboratory-Broad Institute collaboration. Cancer and immune therapies continued to dominate venture funding, accounting for more than 40% of biotech venture activity in H1 2026.

PATIENT & ADVOCACY WATCH

Thirty-five neuromuscular disease patient advocacy organizations sent a joint letter to the Office of Management and Budget urging withdrawal of a proposed federal funding rule that could weaken grant review processes for biomedical research — a reminder of how much behind-the-scenes advocacy work protects the research pipeline patients depend on. Meanwhile in Ireland, Friedreich's Ataxia patients and families rallied outside Leinster House this week as reimbursement for Skyclarys was referred to a specialist review committee — a hard reminder that approval is only step one; access is the real finish line. On a brighter note, ECRD 2026 in Prague brought patient advocates, clinicians, and policymakers together to refine the European Blueprint for Rare Diseases, due for publication this September.

NONPROFIT SPOTLIGHT

This issue's spotlight goes to MS Views and News (MSVN), a patient-centered education and advocacy nonprofit serving the MS, NMOSD, MOGAD, myasthenia gravis, and broader rheumatological-conditions communities through expert-led education, a robust content library, and worldwide programming. MSVN keeps its calendar full of real, in-person connection — including a free educational event in Madison, WI on July 26, bringing together patients, caregivers, advocates, and healthcare professionals for a day of learning and motivation (registration required). If you're in the area or want to support their work, it's worth a look.

THE TALENT ANGLE

The mid-2026 life-sciences hiring data tells a more nuanced story than the "biotech is frozen" narrative suggests. Across thousands of active postings tracked in June, big pharma and CDMOs are hiring in volume, and roughly 17% of open roles sit at mid-senior level or above. My read from the search side: the market isn't frozen, it's selective. Companies are prioritizing candidates who've done the specific thing before — built a function from scratch, launched in a new therapeutic area, or navigated a first US launch — over broad generalist experience. If you're a candidate, lean into your "first-of-its-kind" moments on your resume, even if your title doesn't scream it.

WHAT I'M READING / WATCHING / GRATEFUL FOR

I'm grateful this week for candidates who show up to a first call ready to talk honestly about the messy, non-linear parts of their career path — those are usually the most interesting stories, and often the best hires. On my reading list: catching up on the latest EveryLife Foundation policy updates before my next few candidate conversations. As always, thank you for being part of this community — see you next week.

Warmly,
Ronith
— BlueGene Precision Partners | Fractional Recruiting & Advisory for Life Sciences